Claritev Corporation, a technology, data, and insights company, has announced its financial results for the second quarter of 2025. The company reported revenues of $241.6 million, marking a 3.5% increase compared to the $233.5 million in revenues for the same period in 2024. Claritev also reported a net loss of $62.6 million for Q2 2025, a significant improvement from the net loss of $576.7 million in Q2 2024. The adjusted EBITDA for Q2 2025 was $154.0 million, up from $146.7 million in the prior year. Claritev's updated outlook for the full year 2025 projects revenues to be flat to a 2% increase from FY 2024. The company maintained its adjusted EBITDA margin guidance of 62.5% to 63.5%. Capital expenditures are expected to rise, with revised guidance increasing from $155 million-$165 million to $170 million-$180 million. The effective tax rate guidance remains unchanged at 25% to 28%. Free cash flow guidance has been updated from a negative range of $(75) million to $(65) million to a range of $(20) million to $20 million. Claritev's President and CEO, Travis Dalton, emphasized the company's commitment to making healthcare more affordable and transparent, with a focus on driving results across expanded markets. The company has seen success with renewals, new deals, and partnerships in key areas.